Vasileios Periklis Papadopoulos

Prof. Vasileios Periklis Papadopoulos

Department of Medicine, Democritus University of Thrace, Alexandroúpoli, Anatolikí Makedonía kai Thráki, Greece
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 September 2021 in JCI Insight
Verified
Journal Article
Open access
PDF file
ACAkrivi Chrysanthopoulou
Akrivi Chrysanthopoulou
EGEugenia Gkaliagkousi
Eugenia Gkaliagkousi
ALAntonios Lazaridis
Antonios Lazaridis
SAStella Arelaki
Stella Arelaki
PPPanagiotis Pateinakis
Panagiotis Pateinakis
PSPanagiotis Skendros
Panagiotis Skendros
Innate immunity and chronic inflammation are involved in atherosclerosis and atherothrombosis, leading to target organ damage in essential hypertension (EH). However, the role of neutrophils in EH is still elusive. We investigated the association between angiotensin II (Ang II) and neutrophil extracellular traps (NETs) in pathogenesis of EH. Plasma samples, kidney biopsies, and surgical specimens of abdominal aortic aneurysms (AAAs) from patients with EH were used. Cell-based assays, NETs/human aortic endothelial cell cocultures, and in situ studies were performed. Increased plasma levels of NETs and tissue factor (TF) activity were detected in untreated, newly diagnosed patients with EH. Stimulation of control neutrophils with plasma from patients with untreated EH generated TF-enriched NETs promoting endothelial collagen production. Ang II induced NETosis in vitro via an ROS/peptidylarginine deiminase type 4 and autophagy-dependent pathway. Circulating NETs and thrombin generation levels were reduced substantially in patients with EH starting treatment with Ang II receptor blockers, whereas their plasma was unable to trigger procoagulant NETs. Moreover, TF-bearing NETotic neutrophils/remnants accumulated in sites of interstitial renal fibrosis and in the subendothelial layer of AAAs. These data reveal the important pathogenic role of an Ang II/ROS/NET/TF axis in EH, linking thromboinflammation with endothelial dysfunction and fibrosis.

19 August 2022 in Science Advances
Verified
Journal Article
Open access
PSPanagiotis Skendros
Panagiotis Skendros
GGGeorgios Germanidis
Georgios Germanidis
DMDimitrios C. Mastellos
Dimitrios C. Mastellos
CAChristina Antoniadou
Christina Antoniadou
EGEfstratios Gavriilidis
Efstratios Gavriilidis
JLJohn D. Lambris
John D. Lambris
Complement C3 activation contributes to COVID-19 pathology, and C3 targeting has emerged as a promising therapeutic strategy. We provide interim data from ITHACA, the first randomized trial evaluating a C3 inhibitor, AMY-101, in severe COVID-19 (PaO2/FiO2 ≤ 300 mmHg). Patients received AMY-101 ( n = 16) or placebo ( n = 15) in addition to standard of care. AMY-101 was safe and well tolerated. Compared to placebo (8 of 15, 53.3%), a higher, albeit nonsignificant, proportion of AMY-101–treated patients (13 of 16, 81.3%) were free of supplemental oxygen at day 14. Three nonresponders and two placebo-treated patients succumbed to disease-related complications. AMY-101 significantly reduced CRP and ferritin and restrained thrombin and NET generation. Complete and sustained C3 inhibition was observed in all responders. Residual C3 activity in the three nonresponders suggested the presence of a convertase-independent C3 activation pathway overriding the drug’s inhibitory activity. These findings support the design of larger trials exploring the potential of C3-based inhibition in COVID-19 or other complement-mediated diseases.

23 March 2021 in Diabetology International
Verified
Journal Article
Closed access
PDF file
Vasileios Periklis PapadopoulosVasileios Periklis Papadopoulos
Vasileios Periklis Papadopoulos
MKMarios-Vasileios Koutroulos
Marios-Vasileios Koutroulos
DZDimitra-Georgia Zikoudi
Dimitra-Georgia Zikoudi
SBStefania-Aspasia Bakola
Stefania-Aspasia Bakola
PAPeny Avramidou
Peny Avramidou
DFDimitrios K. Filippou
Dimitrios K. Filippou

17 October 2020 in SN Comprehensive Clinical Medicine
Verified
Journal Article
Open access
PDF file
Vasileios Periklis PapadopoulosVasileios Periklis Papadopoulos
Vasileios Periklis Papadopoulos
NANikolaos Apergis
Nikolaos Apergis
DFDimitrios K. Filippou
Dimitrios K. Filippou
Several studies propose that nocturia, which is common among obstructive sleep apnea (OSA) patients, might be benefited from continuous positive airway pressure (CPAP) treatment. However, related literature remains obscure and thus needs further consolidation and clarification. The present study aimed to provide further evidence regarding potent correlation between CPAP and nocturia in OSA patients. Five hundred and thirty publications were selected after a search in PubMed, Cochrane Library, ClinicalTrials.gov, Google Scholar databases, as well as in unpublished literature. Study eligibility criteria were fulfilled by 11 studies. A systematic review and meta-analysis with subgroup analyses and meta-regressions examined 11 means regarding nocturia rates before and after treatment with CPAP in a total of 830 patients. Mean differences (MD) and confidence intervals (CI) were estimated using random effects model. The study was registered to PROSPERO database (ID: 160600). Nocturia rates are diminished after CPAP treatment, when compared with nocturia rates before CPAP treatment: Overall MD = − 1.13, 95% CI: [− 1.48, − 0.78], P < 0.001; however, increased heterogeneity (I2 = 93%, P = < 0.001) was observed. No statistically significant publication bias was detected (Eggers’ regression P = 0.095; Begg and Mazumdar’s P = 1.000). Meta-regression revealed that the beneficial impact of CPAP treatment regarding nocturia episodes is independently enhanced in patient groups with ≤ 60% severe OSA cases (P = 0.001), ≤ 50 years old (P = 0.001), and > 27 mg/m2 BMI (P = 0.012). Nocturia is alleviated in CPAP-treated OSA patients; CPAP beneficial effect is independently correlated with younger age, increased BMI, and less severe cases.

22 February 2025 in Dentistry Journal
Verified
Journal Article
Open access
PDF file
ZTZoi Maria Thomaidi
Zoi Maria Thomaidi
CTCharalambos Tsatsarelis
Charalambos Tsatsarelis
Vasileios Periklis PapadopoulosVasileios Periklis Papadopoulos
Vasileios Periklis Papadopoulos
Background/Objectives: The mental foramen (MF) constitutes a passage for mental nerves and vessels, and it is a crucial anatomical landmark in the body of the mandible. The accessory mental foramen (AMF) is a small, addable foramen proximate to the MF, and it is mainly located posteriorly. The AMF is a rare anatomical variation in human mandibles that must be taken into consideration throughout dental and surgical operations. We aimed to assess the incidence and perform morphological and morphometric analyses of AMFs in the human dry mandibles of the Greek population, in addition to a relevant systematic review and meta-analysis of global data. Methods: We studied 114 human adult dry mandibles of unknown gender and age available from the Laboratory of Anatomy, Medical School, Democritus University of Thrace, Greece. We used the search term “accessory mental foramen” in the PubMed, Scopus, and Google Scholar databases to detect all publications of the last 50 years reporting the prevalence and morphology of AMFs in dry mandibles; the search ended on 13 January 2025. Quality assessments were performed using the relevant Joanna Briggs Institute tool. Data were synthesized with the random-effects REML model after Freeman–Tukey double arcsine transformationusing STATA 18. No external funding was received. The PROSPERO CRD is 42025638135. Results: According to our data, the MF was present in all observed mandibles, and it was bilateral. Nine AMFs (five right/four left; five round/four oval; six posterior/three anterior to the MF) were found in seven mandibles (five single and two double), and all were unilateral. AMFs presented a mean diameter of 0.96 ± 0.43 mm and mean distances of 4.12 ± 2.15 mm from the MF, 12.68 ± 4.10 mm from the alveolar ridge, and 11.92 ± 1.57 mm from the lower border of the mandible. Furthermore, 27 publications were included in the meta-analysis; the combined AMF prevalence was 6.1% (95% CI: 4.8–7.6%; I2 60%), the combined mean vertical axis was 1.18 ± 0.61 mm, and the combined mean distance from the MF was 3.64 ± 2.29 mm. Bilateral AMFs were detected in 2.1% of AMF cases. An oval shape was described in 37.3% of AMFs. No publication bias was detected. Conclusions: AMFs are not considered rare, and they are occasionally bilateral or even multiple in number. Moreover, they demonstrate considerable variation regarding their size, shape, anddistance from the MF, alveolar ridge, and lower border of the mandible. Dental surgeons must be aware of AMFs’ anatomical variations during surgical and anesthetic planning in order to effectively prevent or mitigate the risk of postoperative complications, such as pain, anesthesia, injury, and other adverse outcomes.

27 September 2023 in World Journal of Hepatology
Verified
Journal Article
Open access
Vasileios Periklis PapadopoulosVasileios Periklis Papadopoulos
Vasileios Periklis Papadopoulos
KMKonstantinos Mimidis
Konstantinos Mimidis
Surrogate endpoints are needed to estimate clinical outcomes in primary sclerosing cholangitis (PSC). Serum alkaline phosphatase was among the first markers studied, but there is substantial variability in alkaline phosphatase levels during the natural history of PSC without intervention. The Mayo risk score incorporates noninvasive variables and has served as a surrogate endpoint for survival for more than two decades. Newer models have better test performance than the Mayo risk score, including the primary sclerosing risk estimate tool (PREsTo) model and UK-PSC score that estimate hepatic decompensation and transplant free survival, respectively. The c-statistics for transplant-free survival for the Mayo risk model and the long-term UK-PSC model are 0.68 and 0.85, respectively. The c-statistics for hepatic decompensation for the Mayo risk model and PREsTo model are 0.85 and 0.90, respectively. The Amsterdam-Oxford model included patients with large duct and small duct PSC and patients with PSC-autoimmune hepatitis overlap and had a c-statistic of 0.68 for transplant-free survival. Other noninvasive tests that warrant further validation include magnetic resonance imaging, elastography and the enhanced liver fibrosis score. Prognostic models, noninvasive tests or a combination of these surrogate endpoints may not only serve to be useful in clinical trials of investigational agents, but also serve to inform our patients about their prognosis.